...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on

Yes nothing new...

but the abstract does not show the change in eGFR.  In the clinical trials document, Secondary Outcomes Measures #12 is the change in eGFR in the < 60 cohort.  That is what we are missing.  Hopefully that is what they show at the presentation.  If not, then who knows?

 

abstract is on page 181 or 182....took me a long time scrolling through...started from the bottom

Share
New Message
Please login to post a reply